Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98.6M
-
Number of holders
-
114
-
Total 13F shares, excl. options
-
59.9M
-
Shares change
-
-5.5M
-
Total reported value, excl. options
-
$612M
-
Value change
-
-$15.9M
-
Put/Call ratio
-
0.1
-
Number of buys
-
63
-
Number of sells
-
-38
-
Price
-
$10.22
Significant Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q1 2024
132 filings reported holding SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q1 2024.
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) has 114 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 59.9M shares
of 98.6M outstanding shares and own 60.76% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (11.1M shares), RA CAPITAL MANAGEMENT, L.P. (10.9M shares), ORBIMED ADVISORS LLC (9.24M shares), SR ONE CAPITAL MANAGEMENT, LP (4.01M shares), FRANKLIN RESOURCES INC (2.95M shares), VANGUARD GROUP INC (2.89M shares), BlackRock Inc. (2.66M shares), K2 PRINCIPAL FUND, L.P. (2.22M shares), Nextech Invest Ltd. (1.91M shares), and STATE STREET CORP (1.6M shares).
This table shows the top 114 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.